Rifaquizinone
Rifaquizinone (RFQ, CBR-2092, TNP-2092) is an experimental antibiotic medication developed in China for the treatment of bacterial infections such as drug-resistant strains of Staphylococcus aureus. It is an orally active prodrug which is also a codrug, being cleaved inside the body to two active components, with half of the molecule being a rifamycin derivative, and the other half a quinolone antibiotic. It is in clinical trials for joint infections following surgery and acute bacterial skin and skin structure infections.